BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: Conversely, when we compared potencies of the two BCL-2 inhibitors in EWS-FLI1 negative cancer cells, U2OS osteosarcoma and KBM7 chronic myeloid leukemia cell lines, we observed markedly different patterns than in EwS.